Core Insights - Cytokinetics is scheduled to report its fourth quarter results on February 27, 2025, at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM to discuss operational and financial results and future outlook [1][2] Company Overview - Cytokinetics is a late-stage biopharmaceutical company specializing in muscle biology, focused on developing drug candidates for diseases that compromise muscle performance [3] - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial for obstructive hypertrophic cardiomyopathy (HCM) [3] - Cytokinetics is also developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophies and impaired skeletal muscle function [3]

Core Insights - Cytokinetics has appointed Robert E. Landry to its Board of Directors, enhancing the company's financial and operational expertise as it approaches potential commercialization of its first medicine [2][3] - Landry has over 30 years of experience in the pharmaceutical industry, including 11 years as CFO at Regeneron Pharmaceuticals, where he played a key role in the company's growth and acquisitions [2][3][4] - The company is preparing for the potential approval and launch of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [5] Company Overview - Cytokinetics is a late-stage biopharmaceutical company focused on muscle biology and developing treatments for diseases that compromise muscle performance [5] - The company is also developing other drug candidates, including omecamtiv mecarbil for heart failure and CK-586 for heart failure with preserved ejection fraction [5] Leadership and Expertise - Robert I. Blum, President and CEO of Cytokinetics, emphasized the importance of Landry's financial expertise in guiding the company towards sustainable growth and commercialization [3] - Landry's previous experience includes significant roles at Wyeth and Pfizer, where he held various corporate and operational positions [4]

Company Overview - Cytokinetics is a late-stage biopharmaceutical company specializing in muscle biology, focused on developing drug candidates for diseases that compromise muscle performance [3] - The company aims to improve patient lives through global access to innovative medicines [3] Upcoming Event - Robert I. Blum, President and CEO of Cytokinetics, will participate in a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 4:40 PM Eastern Time [1] Product Development - Cytokinetics is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial for obstructive hypertrophic cardiomyopathy (HCM) [3] - The company is also developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophies and impaired skeletal muscle function [3]

Legal Investigation - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Cytokinetics, Inc (CYTK) regarding potential self-dealing [1] - Shareholders may be entitled to damages and corporate governance reforms as a result of the investigation [1] Shareholder Participation - Long-term CYTK stockholders are encouraged to contact Kuehn Law for a free consultation and case evaluation [2] - Shareholder participation is important for maintaining the integrity and fairness of financial markets [3] Contact Information - Kuehn Law, PLLC can be reached via email at [email protected] or by phone at (833) 672-0814 [2][3] - The law firm is located at 53 Hill Street, Suite 605, Southampton, NY 11968 [3]

Total of $100,000 Awarded to Five Patient Advocacy Organizationsto Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its seventh annual Communications Grant Program, intended to support increased communications, awareness building and community engagement. Five grants in the amount of $20,000 each were awarded this year to patient advocacy organizations serving the hypertrop ...

Shares of Cytokinetics (CYTK) gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure patients. The intended patient population includes those with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) ≥60%.   The primary goal of the phase II AMBER-HFpEF study is to evaluate the safety and tolerability profile of CK-586 compared to plac ...

Stifel initiated coverage on Cytokinetics Incorporated CYTK, noting the company’s catalyst rich one to two years.The M&A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 trial data of aficamten in December 2023. However, last year, Novartis AG NVS decided to step back from pursuing the Cytokinetics deal.Amgen Inc AMGN, AstraZeneca Plc AZN, and Johnson & Johnson JNJ also all popped up as potential suitors, though the stock faded from there as a deal never materialized.Also R ...

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) --  Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF) is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial of CK-4021586 (CK-586) in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejec ...

PDUFA Target Action Date for Aficamten Set for September 26, 2025;Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to Becoming Leading Muscle Biology Specialty Biopharma Company SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030, five-year strategic objectives designed to prope ...

Core Insights - Cytokinetics, Inc. is preparing for the potential approval and commercial launch of aficamten for obstructive hypertrophic cardiomyopathy (HCM) in the U.S. by September 26, 2025, with significant milestones planned for 2025 [1][3][4] - The company has outlined its Vision 2030, aiming to become a leading muscle-focused specialty biopharmaceutical company, with strategic objectives to enhance patient access to innovative medicines [2][10] 2025 Milestones - Aficamten is expected to be commercially launched in the U.S. in the second half of 2025, pending FDA approval [7] - The company plans to continue patient enrollment in the COMET-HF trial for omecamtiv mecarbil through 2025, with completion expected in 2026 [4] - Enrollment for the AMBER-HFpEF trial of CK-586 is set to be completed in the second half of 2025 [5] Clinical Trials and Development - The MAPLE-HCM trial results, comparing aficamten to metoprolol, are anticipated in the first half of 2025 [7] - The ACACIA-HCM trial for aficamten in non-obstructive HCM is expected to complete enrollment in the second half of 2025 [7] - The CEDAR-HCM trial for pediatric patients is also set to complete enrollment in the second half of 2025 [7] Vision 2030 Objectives - The Vision 2030 roadmap includes goals to deliver product approvals, achieve broad access to medicines, and promote equitable access [10][14] - The company aims to reach over 100,000 patients globally with its medicines and extend its leadership in muscle biology through multiple therapeutic modalities [14]